Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07169500 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169500 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.” NCT07169500 ↗ |